利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

77 条记录 (耗时 0.064 秒)

    Cyclic regimens using quinazolinone and benzoxazine derivatives
    1.
    发明授权
    Cyclic regimens using quinazolinone and benzoxazine derivatives 失效
    使用喹唑啉酮和苯并恶嗪衍生物的循环方案

    公开(公告)号：US06498154B1

    公开(公告)日：2002-12-24

    申请号：US09552357

    申请日：2000-04-19

    申请人： Gary S. Grubb ,  Lin Zhi ,  Todd K. Jones ,  Puwen Zhang ,  James P. Edwards ,  Andrew Fensome ,  Eugene A. Terefenko ,  Jay E. Wrobel ,  Christopher M. Tegley

    发明人： Gary S. Grubb ,  Lin Zhi ,  Todd K. Jones ,  Puwen Zhang ,  James P. Edwards ,  Andrew Fensome ,  Eugene A. Terefenko ,  Jay E. Wrobel ,  Christopher M. Tegley

    IPC分类号： A61K3156

    CPC分类号： A61K31/565 ,  A61K31/57 ,  A61K45/06 ,  A61K2300/00

    摘要： This invention relates to cyclic combination therapies utilizing, in combination with progestins, estrogens, or both, compounds which are progesterone receptor antagonists of the general structure: wherein: R1 and R2 are H, CORA, or NRBCORA, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclic; or R1 and R2 fuse to form 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic rings; RA is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl groups; RB is H or alkyl; R3 is H, OH, NH2, CORC or alkyl, alkenyl, or alkynyl; RC is H, alkyl, aryl, alkoxy, or aminoalkyl; R4 is H, halogen, CN, NO2, alkyl, alkynyl, alkoxy, amino or aminoalkyl; R5 is benzene or 5- or 6-membered heterocyclic ring; R6 is H or alkyl; G1 is O, NR7, or CR7R8; G2 is CO or CR7R8; provided that when G1 is O, G2 is CR7R8, and G1 and G2 cannot both be CR7R8; R7 and R8 are H or an optionally substituted alkyl, aryl, or heterocyclic moiety; or pharmaceutically acceptable salt thereof. These methods may be used for contraception or treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minimization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.

    摘要翻译： 本发明涉及利用与孕激素，雌激素或两者作为一般结构的孕酮受体拮抗剂的化合物的环状组合疗法：其中：R1和R2是H，CORA或NRBCORA，烷基，烯基，炔基，环烷基 ，芳基或杂环基; 或R1和R2融合形成3至8元螺环烷基，烯基或杂环; RA为H或任选取代的烷基，芳基，烷氧基或氨基烷基; RB是H或烷基; R3是H，OH，NH2，CORC或烷基，烯基或炔基; RC是H，烷基，芳基，烷氧基或氨基烷基; R4是H，卤素，CN，NO2，烷基，炔基，烷氧基，氨基或氨基烷基; R5是苯或5-或6-元杂环; R6是H或烷基; G1是O，NR7或CR7R8; G2为CO或CR7R8; 条件是当G1为O时，G2为CR7R8，G1和G2不能为CR7R8; R 7和R 8是H或任选取代的烷基，芳基或杂环部分; 或其药学上可接受的盐。 这些方法可用于避孕或治疗和/或预防继发性闭经，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症; 多囊卵巢综合征，子宫内膜，卵巢，乳腺，结肠，前列腺的癌和腺癌，或副作用最小化或周期性月经出血。 本发明的额外用途包括刺激食物摄取。

    Combination regimens using progesterone receptor modulators
    2.
    发明授权
    Combination regimens using progesterone receptor modulators 失效
    使用孕酮受体调节剂的联合治疗方案

    公开(公告)号：US06759408B2

    公开(公告)日：2004-07-06

    申请号：US10141792

    申请日：2002-05-09

    申请人： Gary S. Grubb ,  Puwen Zhang ,  Eugene A. Terefenko ,  Andrew Fensome ,  Jay E. Wrobel ,  Horace Fletcher, III ,  James P. Edwards ,  Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi

    发明人： Gary S. Grubb ,  Puwen Zhang ,  Eugene A. Terefenko ,  Andrew Fensome ,  Jay E. Wrobel ,  Horace Fletcher, III ,  James P. Edwards ,  Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi

    IPC分类号： A61K31535

    CPC分类号： A61K31/535 ,  A61K31/56 ,  Y10S514/843 ,  A61K2300/00

    摘要： This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1 and R2 may be single substituents or fused; R3 is H, OH, NH2, C1 to C6 alkyl, CORC, or optionally substituted C1 to C6 alkyl, C3 to C6 alkenyl, or alkynyl; RC is H, or optionally substituted C1 to C3 alkyl, aryl, C1 to C3 alkoxy, or C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, or optionally substituted C1 to C6 alkyl, alkynyl, C1 to C6 alkoxy, amino, or C1 to C6 aminoalkyl; and R5 is a benzene ring, a five or six membered heterocyclic ring; or pharmaceutically acceptable salt thereof. Methods of treatment include contraception, secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, carcinomas, adenocarcinomas minimization of side effects, or food intake stimulation.

    摘要翻译： 本发明涉及使用具有通式结构的孕酮受体的拮抗剂的取代的二氢吲哚衍生物化合物的环状组合疗法和方案：其中R 1和R 2可以是单个取代基或稠合的; R 3是H，OH，NH 2，C 1 -C 6烷基，COR C或任选取代的C 1 -C 6烷基，C 3至C 6烯基或炔基; R C是H或任选取代的C 1至C 3烷基，芳基，C 1至C 3烷氧基或C 1至C 3氨基烷基; R 4是H，卤素，CN，NO 2或任选取代的C 1至C 6烷基，炔基，C 1至C 6烷氧基，氨基或C 1至C 6氨基烷基; 和R 5为苯环，五或六元杂环; 或其药学上可接受的盐。 治疗方法包括避孕，继发性闭经，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症，多囊卵巢综合征，癌，腺癌最小化副作用或食物摄取刺激。

    Combination regimens using progesterone receptor modulators
    3.
    发明授权
    Combination regimens using progesterone receptor modulators 失效
    使用孕酮受体调节剂的联合治疗方案

    公开(公告)号：US06444668B1

    公开(公告)日：2002-09-03

    申请号：US09552350

    申请日：2000-04-19

    申请人： Gary S. Grubb ,  Puwen Zhang ,  Eugene A. Terefenko ,  Andrew Fensome ,  Jay E. Wrobel ,  Horace Fletcher, III ,  James P. Edwards ,  Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi

    发明人： Gary S. Grubb ,  Puwen Zhang ,  Eugene A. Terefenko ,  Andrew Fensome ,  Jay E. Wrobel ,  Horace Fletcher, III ,  James P. Edwards ,  Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi

    IPC分类号： A61K31535

    CPC分类号： A61K31/535 ,  A61K31/56 ,  Y10S514/843 ,  A61K2300/00

    摘要： This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1 and R2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3 is H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 allyl C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, or substituted alknyl, CORC; RC is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, C1 to C6 alkyl, substituted C1 to C6 alkyl alkynyl, or substituted alkynyl, C1 to C6 alkoxy, substituted C1 to C6 alkoxy, amino, C1 to C6 aminoalkyl, or substituted C1 to C6 aminoalkyl; and R5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR6 and containing one or two independent substituents from the group including H, halogen, CN, NO2, amino, and C1 to C3 alkyl, C1 to C3 alkoxy, C1 to C3 aminoalkyl, CORF, or NRGCORF; or pharmaceutically acceptable salt thereof. These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or inmization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.

    摘要翻译： 本发明涉及使用具有以下通式结构的孕酮受体的拮抗剂的取代的二氢吲哚衍生物化合物的环状组合疗法和方案：其中R1和R2可以是单取代基或稠合形成螺环或异 - 螺环; R 3是H，OH，NH 2，C 1至C 6烷基，取代的C 1 -C 6烯丙基C 3至C 6烯基，取代的C 1至C 6烯基，炔基或取代的烷基，CORC; RC为H，C1至C3烷基，取代C1至C3烷基，芳基，取代芳基，C1至C3烷氧基，取代C1至C3烷氧基，C1至C3氨基烷基或取代C1至C3氨基烷基; R 4是H，卤素，CN，NO 2，C 1至C 6烷基，取代的C 1至C 6烷基炔基或取代的炔基，C 1至C 6烷氧基，取代的C 1至C 6烷氧基，氨基，C 1至C 6氨基烷基或取代的C 1至C 6氨基烷基 ; 并且R 5选自具有1,2或3个杂原子的五元或六元环的三取代苯环，所述杂原子包括O，S，SO，SO 2或NR 6，并且包含一个或两个独立的取代基，包括H， 卤素，CN，NO 2，氨基和C 1至C 3烷基，C 1至C 3烷氧基，C 1至C 3氨基烷基，CORF或NRGCORF; 或其药学上可接受的盐。 这些治疗方法可用于避孕或治疗和/或预防继发性闭经，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症; 多囊卵巢综合征，子宫内膜癌，卵巢癌，乳腺癌，结肠癌，前列腺癌，腺癌，副作用或周期性月经出血。 本发明的额外用途包括刺激食物摄取。

    Cyclothiocarbamate derivatives as progesterone receptor modulators
    5.
    发明授权
    Cyclothiocarbamate derivatives as progesterone receptor modulators 失效
    环硫代氨基甲酸酯衍生物作为孕酮受体调节剂

    公开(公告)号：US07081457B2

    公开(公告)日：2006-07-25

    申请号：US10140034

    申请日：2002-05-06

    申请人： Puwen Zhang ,  Andrew Fensome ,  Eugene A. Terefenko ,  Lin Zhi ,  Todd K. Jones ,  James P. Edwards ,  Christopher M. Tegley ,  Jay E. Wrobel ,  Mark A. Collins

    发明人： Puwen Zhang ,  Andrew Fensome ,  Eugene A. Terefenko ,  Lin Zhi ,  Todd K. Jones ,  James P. Edwards ,  Christopher M. Tegley ,  Jay E. Wrobel ,  Mark A. Collins

    IPC分类号： A61K31/535 ,  C07D295/00 ,  C07D265/12

    CPC分类号： A61K31/536 ,  A61K31/538 ,  C07D265/18 ,  C07D413/04

    摘要： Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R1 and R2 are selected from the group of H, optionally substituted C1 to C6 alkyl, alkenyl, alkynyl, or alkynyl groups C3 to C8 cycloalkyl, aryl, substituted aryl, or heterocyclic groups, or CORA or NRBCORA; or R1 and R2 are fused to form an optionally substituted ring structure as defined herein; RA and RB are as defined herein; R3 is H, OH, NH2, CORC, or optionally substituted C1 to C6 alkyl, C3 to C6 alkenyl, or alkynyl groups; RC is as defined herein; Q1 is S, NR7, or CR8R9; R5 is an optionally trisubstituted benzene ring or an optionally substituted five or six membered heterocyclic ring.

    摘要翻译： 提供使用孕酮受体激动剂用于避孕的化合物和单独或与雌​​激素受体激动剂或孕酮受体拮抗剂联合治疗孕激素相关性疾病的方法。 这些化合物具有以下结构：其中R 1和R 2选自H，任选取代的C 1至C 1 - C 6烷基，链烯基，炔基或炔基C 3至C 8环烷基，芳基，取代的芳基或杂环基，或COR A 或或 B 或R 1和R 2 2稠合形成如本文所定义的任选取代的环结构; R＆lt; A＆gt;和＆lt; B＆gt; B＆gt;如本文所定义; R 3是H，OH，NH 2，COR C或任选取代的C 1至C

    1,2,3,4-tetrahydro-2-thioxo-quinolinyl and 1,2,3,4-tetrahydro-2-oxo-quinolinyl derivatives as progesterone receptor modulators
    6.
    发明授权
    1,2,3,4-tetrahydro-2-thioxo-quinolinyl and 1,2,3,4-tetrahydro-2-oxo-quinolinyl derivatives as progesterone receptor modulators 失效
    1,2,3,4-四氢-2-硫代 - 喹啉基和1,2,3,4-四氢-2-氧代喹啉基衍生物作为孕酮受体调节剂

    公开(公告)号：US06693103B2

    公开(公告)日：2004-02-17

    申请号：US10023063

    申请日：2001-12-17

    申请人： Puwen Zhang ,  Andrew Fensome ,  Eugene A. Terefenko ,  Jay E. Wrobel ,  James P. Edwards ,  Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi

    发明人： Puwen Zhang ,  Andrew Fensome ,  Eugene A. Terefenko ,  Jay E. Wrobel ,  James P. Edwards ,  Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi

    IPC分类号： C07D215227

    CPC分类号： C07D215/227 ,  A61K31/4704 ,  A61K31/517 ,  A61K31/536 ,  C07D215/38 ,  C07D239/80 ,  C07D265/16 ,  C07D413/04

    摘要： This invention provides compounds which are agonists and antagonists of the progesterone receptor having the general structure: wherein: R1 and R2 are independently selected from H, CORA, or NRBCORA, or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclic moieties; or R1 and R2 are fused to form: 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic rings; RA is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl groups; RB is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl; R3 is H, OH, NH2, CORC or optionally substituted alkyl, alkenyl, or alkynyl; RC is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; R4 is H, halogen, CN, NO2, or optionally substituted alkyl alkynyl, alkoxy, amino or aminoalkyl; R5 is an optionally substituted benzene or five or six membered ring with 1, 2, or 3 heteroatoms selected from O, S, SO, SO2 or NR6; R6 is H or C1 to C3 alkyl; G1 is O, NR7, or CR7R8; G2 is CO, CS, or CR7R8; provided that when G1 is O, G2 is CR7R8, and G1 and G2 cannot both be CR7R8; R7 and R8 are H or an optionally substituted alkyl, aryl, or heterocyclic moiety; or pharmaceutically acceptable salt thereof, and methods using these compounds in mammals as agonists or antagonists of the progesterone receptor.

    摘要翻译： 本发明提供作为孕酮受体的激动剂和拮抗剂的化合物，其具有以下通式结构：其中：R 1和R 2独立地选自H，COR A或NR C COR 3， 或任选取代的烷基，烯基，炔基，环烷基，芳基或杂环部分;或R 1和R 2稠合形成：3至8元螺环烷基，烯基或杂环; R A是H或任选取代的烷基，芳基，烷氧基或氨基烷基; R B是H，C 1至C 3烷基或取代的C 1至C 3烷基; R 3是H，OH，NH 2，COR C或任选取代的烷基，烯基或炔基; R C是H或任选取代的烷基，芳基，烷氧基或氨基烷基; R 4是H，卤素，CN，NO 2或任选取代的烷基炔基，烷氧基，氨基或氨基烷基; R 5是任选取代的苯或具有1,2或3个选自O，S，SO，SO 2或NR 6的杂原子的五或六元环; R 6是H或C 1至C 3烷基; G1是O，NR7或CR7R8; G2是CO，CS或CR7R8; 条件是当G1为O时，G2为CR7R8，G1和G2不能为CR7R8; R 7和R 8是H或任选取代的烷基，芳基或杂环部分; 或其药学上可接受的盐，以及在哺乳动物中使用这些化合物作为孕酮受体的激动剂或拮抗剂的方法。

    Cyclic urea and cyclic amide derivatives
    9.
    发明授权
    Cyclic urea and cyclic amide derivatives 失效
    环状脲和环状酰胺衍生物

    公开(公告)号：US06369056B1

    公开(公告)日：2002-04-09

    申请号：US09552356

    申请日：2000-04-19

    申请人： Puwen Zhang ,  Arthur A. Santilli ,  Andrew Fensome ,  Eugene A. Terefenko ,  Andrew Q. Viet ,  Jay E. Wrobel ,  James P. Edwards ,  Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi

    发明人： Puwen Zhang ,  Arthur A. Santilli ,  Andrew Fensome ,  Eugene A. Terefenko ,  Andrew Q. Viet ,  Jay E. Wrobel ,  James P. Edwards ,  Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi

    IPC分类号： A61K31535

    CPC分类号： C07D498/04

    摘要： This invention provides compounds of the formula: wherein: A, B and D are N or CH, with the proviso that A, B and D can not all be CH; R1 and R2 are independent substituents selected from H, CORA, NRBCORA, or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or groups; or R1 and R2 are fused to form an optionally substituted 3 to 8 membered spirocyclic or heterocyclic ring; RA is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; RB is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl; R3 is H, OH, NH2, or optionally substituted alkyl, or alkenyl, or CORC; RC is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; R4 is a substituted benzene ring or a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR5; RF is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; RG is H, alkyl, or substituted alkyl; R5 is H or alkyl; Q is O, S, NR6, or CR7R8; R6 is CN, SO2CF3, or optionally substituted alkyl, cycloalkyl, aryl, or heterocyclic ring; R7 and R8 are H, NO2, CN CO2R9, or optionally substituted alkyl, cycloalkyl, aryl, or heterocyclic; R9 is C1 to C3 alkyl; or CR7R8 form a six membered ring of the structure below: W is O or a chemical bond; or a pharmaceutically acceptable salt thereof, as well as their use and pharmaceutical compositions as agonists and antagonists of the progesterone receptor.

    摘要翻译： 本发明提供下式的化合物：其中：A，B和D为N或CH，条件是A，B和D不能全部为CH; R1和R2是选自H，CORA，NRBCORA或任选取代的烷基，烯基，炔基，环烷基，芳基或基团的独立取代基; 或R 1和R 2稠合形成任选取代的3至8元螺环或杂环; RA为H或任选取代的烷基，芳基，烷氧基或氨基烷基; RB是H，C 1至C 3烷基或取代的C 1至C 3烷基; R3是H，OH，NH2或任选取代的烷基或烯基或CORC; RC为H或任选取代的烷基，芳基，烷氧基或氨基烷基; R4是取代的苯环或具有1,2或3个杂原子的五或六元环，所述杂原子包括O，S，SO，SO 2或NR 5; RF是H或任选取代的烷基，芳基，烷氧基或氨基烷基; RG是H，烷基或取代的烷基; R5是H或烷基; Q是O，S，NR6或CR7R8; R6是CN，SO2CF3或任选取代的烷基，环烷基，芳基或杂环; R 7和R 8是H，NO 2，CN CO 2 R 9或任选取代的烷基，环烷基，芳基或杂环; R9为C1至C3烷基; 或CR7R8形成以下结构的六元环：W为O或化学键; 或其药学上可接受的盐，以及它们的用途和药物组合物作为孕激素受体的激动剂和拮抗剂。